Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables (2016 - 2025)

Historic Receivables for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $355789.0.

  • China Pharma Holdings' Receivables fell 9751.47% to $355789.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $355789.0, marking a year-over-year decrease of 9751.47%. This contributed to the annual value of $13.8 million for FY2024, which is 414.48% down from last year.
  • As of Q3 2025, China Pharma Holdings' Receivables stood at $355789.0, which was down 9751.47% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Receivables peaked at $14.4 million during Q4 2023, and registered a low of $275244.0 during Q2 2023.
  • In the last 5 years, China Pharma Holdings' Receivables had a median value of $1.9 million in 2021 and averaged $5.9 million.
  • In the last 5 years, China Pharma Holdings' Receivables surged by 498261.29% in 2024 and then tumbled by 9751.47% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Receivables stood at $2.1 million in 2021, then crashed by 78.94% to $450670.0 in 2022, then soared by 3106.0% to $14.4 million in 2023, then fell by 4.14% to $13.8 million in 2024, then plummeted by 97.43% to $355789.0 in 2025.
  • Its last three reported values are $355789.0 in Q3 2025, $14.0 million for Q2 2025, and $14.0 million during Q1 2025.